BOTULINUM TOXIN A FOR THE MANAGEMENT OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME
https://doi.org/10.21886/2308-6424-2017-5-3-68-78
Abstract
Interstitial Cystitis/Bladder Pain Syndrome is a chronic and debilitating condition that negatively impacts quality of life. Several causes have been postulated in the pathogenesis of this condition; however, the etiology remains unknown. Interstitial сystitis may go undiagnosed for many years because the condition often co-exists with other chronic pain syndromes. Furthermore, the symptoms of Bladder Pain Syndrome vary considerably across patients, therefore no one treatment has shown to be consistently effective in providing relief. Thus, the goal of management of interstitial сystitis remains to provide relief of symptoms in order to improve a patient’s quality of life. intravesical Botulinum toxin A is emerging as a potential new pharmacologic treatment for interstitial сystitis refractory to conventional treatment modalities. The aim of our short review is to assess the efficacy of intravesical Botulinum toxin A in Bladder Pain Syndrome.
About the Authors
V. L. Medvedev
Kuban State Medical University; State Budgetary Healthcare Institution «Research Institution - Regional Clinical Hospital № l of prof. S.V. Ochapovskogo».
Russian Federation
Russian Federation
Medvedev Vladimir Leonidovich, doctor of Medicine, professor and Chairman Department of Urology Kuban State Medical University, head of the Urology and Nephrology Center, the Chief of the urological Service of Krasnodar regional hospital №1, chief specialist of transplantology of Krasnodar region, chief of the Urology Department №2 of Krasnodar Regional Hospital № 1.
Krasnodar.
S. N. Lepetunov
State Budgetary Healthcare Institution «Research Institution - Regional Clinical Hospital № l of prof. S.V. Ochapovskogo».
Russian Federation
Russian Federation
Lepetunov Sergey Nikolaevich, urologist of Urology Department №2 of Krasnodar Regional Hospital № 1.
Krasnodar.
References
1. van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, Elneil S, Fall M, Hohlbrugger G, Irwin P, Mortensen S, van Ophoven A, Osborne JL, Peeker R, Richter B, Riedl C, Sairanen J, Tinzl M, Wyndaele JJ. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60-7. doi: 10.1016/j.eururo.2007.09.019
2. Hanno PM, Burks D, Clemens JQ, Dmochowski R, Erickson D, Fitzgerald MP. AUA guideline for the diagnosis and treatment of inters al cys s/bladder pain syndrome. J Urol. 2011;185(6):2162–70. doi: 10.1016/j.juro.2011.03.064
3. Zaytsev AV, Sharov MN, Pushkar DYu, Khodyreva LA,. Dudareva AA. Chronic pelvic pain. Clinical recommenda ons. Moscow; 2016. (In Russ.)
4. Kogan MI, Belousov II, Sizonov VV. The use of botulinum toxin type A in the correc on of symptoms of impaired urina on in children and adults. Eff ek vnaya farmakoterapiya. 2011;44:10-15. (In Russ.)
5. Jabbari B. Botulinum Toxin Treatment of Pain Disorders. Springer New York Heidelberg Dordrecht London. Springer Science+Business Media New York; 2015.
6. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin A has an noccep ve eff ects in trea ng inters al cys s. Urology. 2004;64:871–5. doi: 10.1016/j.urology.2004.06.073
7. Jhang JF, Jiang YH, Kuo HC. Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis. Int J Urol. 2014;21(1):4955. doi: 10.1111/iju.12317.
8. Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol. 2006;49:704. doi: 10.1016/j.eururo.2005.12.002
9. Ramsay AK, Small DR, Conn IG. Intravesical botulinum toxin type A in chronic interstitial cystitis: results of a pilot study. Surgeon. 2007;5(6):331–3. doi: 10.1016/S1479-666X(07)80084-9
10. Carl S, Grosse J, Laschke S. Treatment of interstitial cystitis with botulinum toxin type A. Eur Urol. 2007;6:248. doi: 10.1016/S1569-9056(07)60896-3
11. Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology. 2007;70(3):463–8. doi: 10.1016/j.urology.2007.04.038
12. Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year follow-up. J Urol. 2008;179(3):1031–4. doi: 10.1016/j.juro.2007.10.032
13. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistension with hydrodistension alone for the treatment of refractory interstitialbcystitis/painful bladder syndrome. BJU Int. 2009;104:657–61. doi: 10.1111/j.1464410X.2009.08495.x
14. El-Bahnasy AE, Farahat YA, El-Bendary M, Mourad SA. Randomized controlled trial of bacillus CalmetteGuerin and botulinum toxin-A for the treatment of refractory interstitial cystitis. UroToday Int J. 2009;2:2–2. doi:10.3834/uij.1944-5784.2008.12.06
15. Giannantoni A, Mearini E, Del Zingaro M, Proietti S, Porena M. Two-year efficacy and safety of botulinum a toxin intravesical injections in patients affected by refractory painful bladder syndrome. Current Drug Delivery. 2010;7(1):1-4
16. Rasheed T, Farahat A, Bahnasy M, Bindary A, Tatawy H. A prospec ve randomized study of intravesical pentosan polysulfate and botulinum toxin-A for the treatment of painful bladder syndrome/inters al cys s. Eur Urol Suppl. 2010;9(2):641.
17. Pinto R, Lopes T, Frias B, Silva A, Silva JA, Silva CM, Cruz C, Cruz F, Dinis P. Trigonal injec on of botulinum toxin A in pa ents with refractory bladder pain syndrome/inters al cys s. Eur Urol. 2010;58(3):366–8. doi: 10.1016/j.eururo.2010.02.031
18. Go sch HP, Miller JL, Yang CC, Berger RE. A pilot study of botulinum toxin for Inters al cys s/painful bladder syndrome. Neurourol Urodyn. 2011;30:93–6. doi: 10.1002/nau.20946
19. Chung SD, Kuo YC, Kuo HC. Intravesical onabotulinumtoxin A injec ons for refractory painful bladder syndrome. Pain Physician. 2012;15:197-202.
20. Kuo HC. Repeated Onabotulinumtoxin-A Injec ons Provide Be er Results than Single Injec on in Treatment of Painful Bladder Syndrome. Pain Physician. 2013;16:E15E23.
21. Lee CL, Kuo HC. Long-Term Effi cacy and Safety of Repeated Intravescial OnabotulinumtoxinA Injec ons Plus Hydrodisten on in the Treatment of Inters al Cys s/ Bladder Pain Syndrome. Toxins. 2015;7(10);4283-4293. doi: 10.3390/toxins7104283
22. Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injec ons reduce bladder pain of inters al cys s/bladder pain syndrome refractory to conven onal treatment – A prospec ve, mul center, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. 2016;35(5):609-14. doi: 10.1002/nau.22760
23. Lorenzo L, Bonillo MA, Arlandis S, Mar nez-Cuenca E, Marzullo L, Broseta E, Boronat F. Hydrodistension plus Onabotulinumtoxin A in bladder pain syndrome refractory to conserva ve treatments. Actas Urol Esp. 2016;40(5):303-8. doi: 10.1016/j.acuro.2015.12.011
24. Akiyama Y, Nomiya A, Niimi A, Yamada Y, Fujimura T, Nakagawa T, Fukuhara H, Kume H, Igawa Y, Homma Y. Botulinum toxin type A injec on for refractory inters al cys s: A randomized compara ve study and predictors of treatment response. Int J Urol. 2015;22(9):835-41. doi: 10.1111/iju.12833
25. Saraswat I, Lawrentschuk N. Botulinum Toxin A in the Treatment of Inters al Cys s/Bladder Pain Syndrome: A Short Review. J Urol Res. 2015;2(1):1021.
Review
For citations:
Medvedev V.L., Lepetunov S.N. BOTULINUM TOXIN A FOR THE MANAGEMENT OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME. Urology Herald. 2017;5(3):68-78. (In Russ.) https://doi.org/10.21886/2308-6424-2017-5-3-68-78
Views:
1885
Email this article 
